Droxidopa (L-DOPS) hydrochloride is a potent, orally active precursor to norepinephrine that elevates standing blood pressure, mitigates orthostatic hypotension symptoms, and enhances standing capability. It holds promise for research in neurogenic orthostatic hypotension (nOH) and alternative attention deficit hyperactivity disorder (ADHD) treatments [1] [2] [3] [4].

Droxidopa hydrochloride (200 mg/kg;i.p.) alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats [2]. Droxidopa hydrochloride (10, 20 mg/kg; i.p.) significantly increases the paw withdrawal latency and suppresses mechanical hypersensitivity to thermal stimulation in 6-OHDA-lesioned rats at the 5th week after surgery [3]. Animal Model: 250-380g male Sprague-Dawley rats [2] Dosage: 200 mg/kg (10 mg/kg, i.p. benserazide was given to the animals at 20 or 30 min prior to L-DOPS injection) Administration: I.p. Result: Significantly decreased hyperactivity of BZ-pretreated SHR/NCrl at 30 (P < 0.01) and 40 min (P < 0.05) post-injection, improved inattention-like behavior of SHR/NCrl, and ameliorated impulsive-like behavior of SHR/NCrl and Wistar rats.